Scholar Rock Holding Stock News

The consensus price target hints at a 246.1% upside potential for Scholar Rock Holding Corporation (SRRK). While empirical research shows that this sought-after metric is hardly effective, an upward t

A venture capital group significantly increased its stake in the company.

The consensus price target hints at a 394.4% upside potential for Scholar Rock Holding Corporation (SRRK). While empirical research shows that this sought-after metric is hardly effective, an upward t

Scholar Rock Holding Corp (NASDAQ: SRRK) announced new data from the Phase 2 TOPAZ trial extension period evaluating apitegromab in non-ambulatory patients with Types 2 and 3 Spinal Muscular Atroph

Scholar Rock Holding Corporation (SRRK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in rai

Scholar Rock Holding Corp (NASDAQ: SRRK) plans to reduce its overall headcount by 25%, and its Chief Medical Officer Yung Chyung will step down by the end of June.  "Parting with employees who hav

Scholar Rock Holding Corporation (SRRK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving hig

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock announces a poster presentation at the 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, March 13 - 16.

Scholar Rock Holding Corporation (SRRK) delivered earnings and revenue surprises of 6.73% and 4.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for

Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundament

Scholar Rock Holding Corp (SRRK) shares closed today at 0.5% above its 52 week low of $21.31, giving the company a market cap of $751M. The stock is currently down 13.8% year-to-date, down 53.4% over the past 12 months, and up 38.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 11.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 147.6% The company's stock price performance over the past 12 months lags the peer average by 1.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Scholar Rock Holding Corp (SRRK) shares closed today at 0.5% above its 52 week low of $21.31, giving the company a market cap of $751M. The stock is currently down 13.8% year-to-date, down 54.6% over the past 12 months, and up 38.1% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 11.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 8.0% lower than its 5-day moving average, 13.8% lower than its 20-day moving average, and 27.0% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 147.6% The company's stock price performance over the past 12 months lags the peer average by 3.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Scholar Rock (NASDAQ:SRRK) and PharmaCyte Biotech (OTCMKTS:PMCBD) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability. Analyst Recommendations This is a breakdown of recent ratings and target prices for Scholar Rock []